Qiagen Registers $127.1M in Employee Stock Options

Nov 18, 2011

NEW YORK (GenomeWeb News) – Qiagen on Thursday filed for the registration of up to $127.1 million in shares in connection to stock options being offered to employees.

The company filed a registration for 9 million shares at a proposed maximum offering price of $14.12 in a Form S-8 filed with the US Securities and Exchange Commission.

The price was based on the average of the high and low sale prices of Qiagen's stock as of Nov. 15, it said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Featured White Papers

Freeze-drying - a manufacturing approach to increase the stability of in vitro diagnostic (IVD) assays

Point of Care Testing Using Smartphone Diagnostic Readers - Download FAQ Guide

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

The Foundry Model is Coming to Molecular Diagnostics, Courtesy of the Semiconductor Industry

Oct

02

Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.

Oct

11

Featured Webinar

Validation of Error-Corrected Sequencing for Hematological Malignancies

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct

23

Featured Webinar

Perspectives on Small RNA Sequencing: Challenges and Complications of Small RNA Library Prep

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Main menu